Fundamentals support it — not a trap.

Published Nov 6, 2026 · Horizon 3-6 months Audited

Edge6/10

Evidence7/10

Entry (close)

$92.58 2026-11-05

Since publish

—

vs SPY

—

3-month verdict

Closes 2027-02-04

Thesis

SCHW de-rated ~25% in forward P/E terms (from ~17-22x to ~11-12x forward) while earnings power inflected upward — record revenue, record asset flows, 54.8% adjusted pretax margin, and 2027E EPS of $7.80 (+21% vs 2026E). The technical 'breakout' the scan flags is simply SCHW holding up (+3.5% 1-week) while SPY fell 4.7% and peers IBKR/HOOD fell 11-14%; with 95% idiosyncratic share vs SPY, this is a stock-specific mean-reversion setup, not beta chasing. If the recent down-revision streak stabilizes and the December FOMC hike (78% odds) proves net NIM-positive via reinvestment yields on a positively sloped curve, the stock re-rates toward the $97-119 target band.

Bull case

Earnings power is inflecting (record flows, 29% EPS growth, operating leverage) while the multiple sits at the bottom of its own range — re-rating to even 14-15x 2027E EPS implies $109-117, ~18-26% upside. A December hike on a positively sloped curve lifts reinvestment yields; management says cash sorting is over; October retail trading hit records industry-wide, supporting trading revenue. Consensus targets cluster near $117-119.

Bear case

The NIM miss and loan growth outpacing deposits reveal genuine funding fragility; the 7-day down-revision streak is the leading edge of estimate cuts, and BofA's $82 Underperform target is ~11% below current price. A December hike re-ignites cash sorting into 3.5%+ money-market alternatives (Fidelity's default model), raising sweep costs faster than asset yields reprice. Long-end yields near 5.3% keep AOCI/securities pressure alive. The bounce is a value trap inside a 22.5% drawdown.

What would change our mind

If the 7-day down-revision streak persists for another 3-4 weeks and 2027E EPS falls below ~$7.50, the de-rating is justified — thesis wrong
If October monthly metrics show transactional sweep cash declining materially below ~$490B, management's 'no cash sorting' claim fails
If Q4 results show NIM contracting sequentially despite higher rates, the funding-fragility bear case is confirmed
If the stock breaks below the 52-week low area (~$85) on rising volume, relative strength has failed

Since publication vs SPY · closed horizons are frozen

No price data after the entry date yet.

The full research everything the view rests on

Direct answer to the question asked

SCHW's scan rank is a relative-strength signal, not absolute momentum: the stock is actually down 14% over 3 months and 18.5% below its 52-week high while record Q3 results (revenue +17%, adjusted EPS +29%, record $190B net new assets) and ~800bps of guided operating leverage pushed 2026-27 EPS estimates up 5-6%. Price fell while estimates rose — that is multiple compression into fundamental improvement, the opposite signature of a momentum trap. The residual risk is real but specific: the last 7 days of estimate revisions flipped negative and BofA carries an Underperform on funding/NIM fragility.

Where the edge would come from

What the price assumes

At ~14.2x 2026E EPS and ~11.8x 2027E EPS — the low end of its own recent 14-22x forward range — the price assumes the post-earnings bear case: that NIM misses persist, loan growth outpacing deposits pressures funding costs, and guidance tracking to the low end of ranges signals deceleration. The broad target-cut wave (BMO $97, BofA $82 Underperform, plus Truist/UBS/JPM/GS/WF cuts) shows consensus has already priced meaningful funding fragility.

Why the market may be wrong

The market is extrapolating a 7-day down-revision streak and a NIM miss while underweighting that (1) 3-month revisions are still up 5-6%, (2) management explicitly denied cash sorting is recurring ('not cash sorting in any way'), (3) the curve has turned positively sloped (2s/10s +36bps), which supports reinvestment economics, and (4) organic growth is accelerating, not decelerating — $190B core NNA (+38%) and record managed-investing flows. If December's hike raises reinvestment yields faster than sweep costs, the funding-fragility narrative inverts.

The one thing to watch

The diagnostic that matters: price down 14% in 3 months while 3-month EPS estimates rose ~5% is multiple compression, not deterioration — the exact opposite of a momentum trap, where price runs ahead of revisions. The variable to watch is not the chart but the 7-day revision ledger (currently 8 up/13 down for 2026, 5 up/17 down for 2027): if that stabilizes within 2-3 weeks, the trap thesis dies; if it accelerates for another month, the de-rating was warranted.

Key evidence (8)

Q3 2026 (Oct 15, 2026): record revenue $7.2B +17% YoY; adjusted EPS $1.69 +29% YoY; core NNA $190.4B +38%; adjusted pretax margin 54.8% (+350bps) [T1 SEC exhibits]
FY26 guidance: revenue growth ~17.5-18.5%, ~800bps operating leverage, continued NIM expansion [T1/T4 transcript]
EPS path: 2025 actual $4.65 → 2026E $6.45 → 2027E $7.80; 3-month revisions +4.9%/+6.4% [T2 WSJ / T4 aggregators]
Forward P/E ~11.1-12.4x vs recent range 13.7-21.7x (Jun 2025-Jun 2026) [T4 provider data — verify]
Post-earnings target cuts: BMO to $97, BofA to $82 Underperform; Deutsche Bank called selloff a buying opportunity [T4 aggregator — moderately sourced]
7-day revisions turned negative: 2026 8 up/13 down; 2027 5 up/17 down [T4 Yahoo]
Technicals: $92.58, below 50d SMA $98.82, -18.5% from 52w high; +8.2pts 1-week spread vs SPY; 95% idiosyncratic share (quant tool, 2026-11-05)
Macro: December hike ~78% odds; curve positive (2y 4.48% / 10y 4.86%) [Reuters via T4; Treasury data]

Catalysts and risks

Catalysts

December 8-9 FOMC decision — hike would test funding costs vs reinvestment yields
SCHW October monthly metrics (due mid-November 2026) — sweep balances and DARTs
Q4 2026 earnings (mid-January 2027) — first clean read on NIM trajectory and FY27 guidance
Stabilization or acceleration of the 7-day estimate revision trend

Risks

December hike re-triggers cash sorting and deposit-cost pressure
7-day down revisions broaden into a sustained negative revision cycle
Funding base fragility: loans +35% YoY vs slower deposit growth
Rate-sensitive financial sector repricing continues regardless of company execution
Key bear data points (target cuts, revision counts, $492.8B sweep cash, 3.04% NIM) rest on T4 aggregators, not verified against filings

What to watch

Weekly 2026/2027 EPS revision counts — the single best forward indicator
Mid-November monthly metrics: sweep cash balances and client cash trends
December FOMC and management commentary on deposit betas
Deposit growth vs loan growth gap in the next 10-Q
Whether price reclaims the 50d SMA (~$99) — confirmation of the mean-reversion leg

Market snapshot when the call was made 2026-11-05

Price

Return 1w	+3.5%
Return 1m	-3.1%
Return 3m	-14.0%
Return 6m	+3.8%
Return 1y	-0.4%
From 52-week high	-18.5%
Realized vol, 20d	26.1%
SPY 3m / 1y	-5.2% / +8.6%
QQQ 3m / 1y	-10.5% / +4.5%

Technicals

SCHW technicals as of 2026-11-05: last close $92.58; 20d SMA 91.80 (bearish); 50d SMA 98.82; 12d EMA 91.05; 26d EMA 93.29; RSI 14 52.0 (balanced); 20d vol 26.3%; volume x1.4 vs 20d avg

Sources (24 · T1 = primary filings)

Want a fresh look at SCHW, or another name?

Queue a new deep-research run. Published to the feed when done.

Automated research opinion, published as-is on Nov 6, 2026. Not personalised advice. Figures use end-of-day closes.